FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921092016> ?p ?o ?g. }

• W2921092016 abstract "Osteoarthritis (OA) is a major public health problem characterized by joint pain, fatigue, functional limitation and decreased quality of life of the patient, which results in increased use of healthcare services and high economical costs. A promising novel bioactive cell-free formulation (BIOF2) for cartilage regeneration has recently been tested in pre-clinical and clinical trials, and has demonstrated a success rate similar to that of total joint arthroplasty for the treatment of severe knee OA. The present study evaluated the efficacy of treatment with BIOF2, by including it within a conservative regimen of 'usual medical care' of knee OA, and whether its efficacy was affected in subgroups of patients presenting with comorbidities that exacerbate OA. A prospective, randomized, 2-arm parallel group phase III clinical trial was conducted, which included 105 patients in the 'usual medical care' group (paracetamol/NSAIDs and general care provided by the family physician) and 107 patients in the BIOF2 group (usual medical care + intra-articular BIOF2 application at 0, 1 and 2 months). Two aspects were evaluated at 0, 6 and 12 months: i) Minimal clinically important improvement (MCII), based on 30% improvement of pain from the baseline; and ii) the Patient Acceptable Symptom State (PASS), a questionnaire that determines patient well-being thresholds for articular pain and function. Adverse effects and regular NSAID use were registered. At 12 months, BIOF-2 treatment produced MCII in 70% of the patients and >50% achieved PASS. Excluding the patients with class 2 obesity or malalignment conditions (genu varum or genu valgum >20 degrees), the experimental treatment produced MCII and PASS in 100 and 92% of patients, respectively, compared with 25 and 8% in the group of usual medical care (P<0.001). No patient with malalignment and treatment with BIOF2 achieved PASS. Notably, there were no serious adverse effects. To conclude, BIOF2 is a safe therapeutic alternative that is easy to implement together with usual medical care for knee OA. Trial registration: Cuban Public Registry of Clinical Trials (RPCEC) Database RPCEC00000277. Retrospectively registered June, 2018." @default.
• W2921092016 created "2019-03-22" @default.
• W2921092016 creator A5003513649 @default.
• W2921092016 creator A5013412871 @default.
• W2921092016 creator A5018926727 @default.
• W2921092016 creator A5020368412 @default.
• W2921092016 creator A5024287989 @default.
• W2921092016 creator A5045600738 @default.
• W2921092016 creator A5055139328 @default.
• W2921092016 creator A5056052370 @default.
• W2921092016 creator A5070530471 @default.
• W2921092016 creator A5070889297 @default.
• W2921092016 creator A5072762090 @default.
• W2921092016 creator A5077523242 @default.
• W2921092016 creator A5082474167 @default.
• W2921092016 creator A5083369079 @default.
• W2921092016 creator A5089398720 @default.
• W2921092016 date "2019-03-13" @default.
• W2921092016 modified "2023-10-18" @default.
• W2921092016 title "Patient‑reported health outcomes for severe knee osteoarthritis after conservative treatment with an intra‑articular cell‑free formulation for articular cartilage regeneration combined with usual medical care vs. usual medical care alone: A randomized controlled trial" @default.
• W2921092016 cites W1532180863 @default.
• W2921092016 cites W1552674655 @default.
• W2921092016 cites W1839924590 @default.
• W2921092016 cites W1964641933 @default.
• W2921092016 cites W1975396356 @default.
• W2921092016 cites W2005698849 @default.
• W2921092016 cites W2013200752 @default.
• W2921092016 cites W2021345791 @default.
• W2921092016 cites W2055065987 @default.
• W2921092016 cites W2058223476 @default.
• W2921092016 cites W2065584680 @default.
• W2921092016 cites W2082977653 @default.
• W2921092016 cites W2086340062 @default.
• W2921092016 cites W2088820409 @default.
• W2921092016 cites W2089526417 @default.
• W2921092016 cites W2099716808 @default.
• W2921092016 cites W2104857876 @default.
• W2921092016 cites W2107183970 @default.
• W2921092016 cites W2113748723 @default.
• W2921092016 cites W2119537673 @default.
• W2921092016 cites W2121639328 @default.
• W2921092016 cites W2124433729 @default.
• W2921092016 cites W2127382293 @default.
• W2921092016 cites W2129017458 @default.
• W2921092016 cites W2129281457 @default.
• W2921092016 cites W2130486107 @default.
• W2921092016 cites W2135187860 @default.
• W2921092016 cites W2139454298 @default.
• W2921092016 cites W2159890589 @default.
• W2921092016 cites W2230785318 @default.
• W2921092016 cites W2299367339 @default.
• W2921092016 cites W2332738649 @default.
• W2921092016 cites W2489485402 @default.
• W2921092016 cites W2593948723 @default.
• W2921092016 cites W2594484339 @default.
• W2921092016 cites W2618196413 @default.
• W2921092016 cites W2621493359 @default.
• W2921092016 cites W2776420200 @default.
• W2921092016 cites W2778522453 @default.
• W2921092016 cites W2802756909 @default.
• W2921092016 cites W2898181250 @default.
• W2921092016 cites W2899191704 @default.
• W2921092016 doi "https://doi.org/10.3892/etm.2019.7384" @default.
• W2921092016 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6447772" @default.
• W2921092016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30988711" @default.
• W2921092016 hasPublicationYear "2019" @default.
• W2921092016 type Work @default.
• W2921092016 sameAs 2921092016 @default.
• W2921092016 citedByCount "4" @default.
• W2921092016 countsByYear W29210920162020 @default.
• W2921092016 countsByYear W29210920162021 @default.
• W2921092016 countsByYear W29210920162023 @default.
• W2921092016 crossrefType "journal-article" @default.
• W2921092016 hasAuthorship W2921092016A5003513649 @default.
• W2921092016 hasAuthorship W2921092016A5013412871 @default.
• W2921092016 hasAuthorship W2921092016A5018926727 @default.
• W2921092016 hasAuthorship W2921092016A5020368412 @default.
• W2921092016 hasAuthorship W2921092016A5024287989 @default.
• W2921092016 hasAuthorship W2921092016A5045600738 @default.
• W2921092016 hasAuthorship W2921092016A5055139328 @default.
• W2921092016 hasAuthorship W2921092016A5056052370 @default.
• W2921092016 hasAuthorship W2921092016A5070530471 @default.
• W2921092016 hasAuthorship W2921092016A5070889297 @default.
• W2921092016 hasAuthorship W2921092016A5072762090 @default.
• W2921092016 hasAuthorship W2921092016A5077523242 @default.
• W2921092016 hasAuthorship W2921092016A5082474167 @default.
• W2921092016 hasAuthorship W2921092016A5083369079 @default.
• W2921092016 hasAuthorship W2921092016A5089398720 @default.
• W2921092016 hasBestOaLocation W29210920161 @default.
• W2921092016 hasConcept C126322002 @default.
• W2921092016 hasConcept C141071460 @default.
• W2921092016 hasConcept C142724271 @default.
• W2921092016 hasConcept C159110408 @default.
• W2921092016 hasConcept C168563851 @default.
• W2921092016 hasConcept C1862650 @default.
• W2921092016 hasConcept C197934379 @default.
• W2921092016 hasConcept C204787440 @default.
• W2921092016 hasConcept C2776164576 @default.
• W2921092016 hasConcept C2779951463 @default.
• W2921092016 hasConcept C535046627 @default.

• next